CoDa Therapeutics Achieves Positive Phase 2 Efficacy of NEXAGON® in Chronic Venous Leg Ulcers

Tuesday, May 25, 2010 General News
Email Print This Page Comment
Font : A-A+

69% Reduction in Venous Leg Ulcer Size in High-Dose Arm at 4 Weeks

For More Information, please contact:

CoDa Therapeutics Inc.

Bradford Duft, President and CEO (brad@codatherapeutics.com)

David Pool, CFO (david@codatherapeutics.com)

The Ruth Group (on behalf of CoDa Therapeutics in the US)

Sara Pellegrino – Investors (646-536-7002 / spellegrino@theruthgroup.com)

Jason Rando – Media (646-536-7025 / jrando@theruthgroup.com)



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook